Advanced search
1 file | 117.35 KB

M2e-based universal influenza A vaccine

(2009) VACCINE. 27(45). p.6280-6283
Author
Organization
Abstract
Human influenza causes substantial morbidity and mortality. Currently, licensed influenza vaccines offer satisfactory protection if they match the infecting strain, but they come with significant drawbacks. These vaccines are derived from prototype viruses, containing the hemagglutinin of influenza viruses that are likely to cause the next epidemic. Their usefulness against a future pandemic, however, remains problematic. A vaccine based on the ectodomain of influenza matrix protein 2 (M2e) could overcome these drawbacks. M2e is highly conserved in both human and avian influenza A viruses. The low immunogenicity against natural M2e can be overcome by fusing M2e to an appropriate carrier such as Hepatitis B virus-derived virus-like particles. Such chimeric particles can be produced in a simple and safe bacterial expression system, requiring minimal biocontainment, and can be obtained in a pure form. Experiments in animal models have demonstrated that M2e-based vaccines induce protection against a lethal challenge with various influenza A virus subtypes. Furthermore, the production and use of an effective M2e-vaccine could be implemented at any time regardless of seasonality, both in an epidemic aswell as in a pandemic preparedness program. In animal models, M2e-vaccines administered parenterally or intranasally protect against disease and mortality following challenge with various influenza A strains. Adjuvants suitable for human use improve protection, which correlates with higher anti-M2e antibody responses of defined subtypes. Recently, Phase I clinical studies with M2e-vaccines have been completed, indicating their safety and immunogenicity. Further clinical development of this universal influenza A vaccine candidate is being pursued in order to validate its protective efficacy in humans.
Keywords
VIRUS, PROTECTION, M2 PROTEINS, PROTON CHANNEL, MATRIX PROTEIN-2, ANTIBODY-RESPONSE, EXTRACELLULAR DOMAIN, ADJUVANT, CELLS, IMMUNITY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 117.35 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Fiers, Walter, Marina De Filette, Karim El Bakkouri, Bert Schepens, Kenny Roose, Michael Schotsaert, A Birkett, and Xavier Saelens. 2009. “M2e-based Universal Influenza A Vaccine.” Vaccine 27 (45): 6280–6283.
APA
Fiers, W., De Filette, M., El Bakkouri, K., Schepens, B., Roose, K., Schotsaert, M., Birkett, A., et al. (2009). M2e-based universal influenza A vaccine. VACCINE, 27(45), 6280–6283. Presented at the 3rd European Influenza Conference.
Vancouver
1.
Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, et al. M2e-based universal influenza A vaccine. VACCINE. OXFORD: ELSEVIER SCI LTD; 2009;27(45):6280–3.
MLA
Fiers, Walter et al. “M2e-based Universal Influenza A Vaccine.” VACCINE 27.45 (2009): 6280–6283. Print.
@article{790462,
  abstract     = {Human influenza causes substantial morbidity and mortality. Currently, licensed influenza vaccines offer
satisfactory protection if they match the infecting strain, but they come with significant drawbacks. These
vaccines are derived from prototype viruses, containing the hemagglutinin of influenza viruses that are
likely to cause the next epidemic. Their usefulness against a future pandemic, however, remains problematic.
A vaccine based on the ectodomain of influenza matrix protein 2 (M2e) could overcome these
drawbacks. M2e is highly conserved in both human and avian influenza A viruses. The low immunogenicity
against natural M2e can be overcome by fusing M2e to an appropriate carrier such as Hepatitis B
virus-derived virus-like particles. Such chimeric particles can be produced in a simple and safe bacterial
expression system, requiring minimal biocontainment, and can be obtained in a pure form. Experiments in
animal models have demonstrated that M2e-based vaccines induce protection against a lethal challenge
with various influenza A virus subtypes. Furthermore, the production and use of an effective M2e-vaccine
could be implemented at any time regardless of seasonality, both in an epidemic aswell as in a pandemic
preparedness program. In animal models, M2e-vaccines administered parenterally or intranasally protect
against disease and mortality following challenge with various influenza A strains. Adjuvants suitable for
human use improve protection, which correlates with higher anti-M2e antibody responses of defined
subtypes. Recently, Phase I clinical studies with M2e-vaccines have been completed, indicating their
safety and immunogenicity. Further clinical development of this universal influenza A vaccine candidate
is being pursued in order to validate its protective efficacy in humans.},
  author       = {Fiers, Walter and De Filette, Marina and El Bakkouri, Karim and Schepens, Bert and Roose, Kenny and Schotsaert, Michael and Birkett, A and Saelens, Xavier},
  issn         = {0264-410X},
  journal      = {VACCINE},
  keywords     = {VIRUS,PROTECTION,M2 PROTEINS,PROTON CHANNEL,MATRIX PROTEIN-2,ANTIBODY-RESPONSE,EXTRACELLULAR DOMAIN,ADJUVANT,CELLS,IMMUNITY},
  language     = {eng},
  location     = {Vilamoura, PORTUGAL},
  number       = {45},
  pages        = {6280--6283},
  publisher    = {ELSEVIER SCI LTD},
  title        = {M2e-based universal influenza A vaccine},
  url          = {http://dx.doi.org/10.1016/j.vaccine.2009.07.007},
  volume       = {27},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: